| |
|
|
|
|
|
|
|||
|
G Degliantoni, L Mangoni and V Rizzoli
Bone marrow cells of a 45-year-old female with Philadelphia chromosome
(Ph1)-positive, early-phase chronic myelogenous leukemia (CML), who was
heterozygous for the glucose-6-phosphate dehydrogenase (G6PD) locus, were
pretreated in vitro with 4-hydroperoxycyclophosphamide (4-HC) and tested
for G6PD activity in several colony formation assays and for karyotypic
abnormalities. All cells within the mixed (CFU-GEMM), the erythroid burst
(BFU-E), and the granulocyte-macrophage (CFU-GM) colonies expressed type A
and type B G6PD activity and a normal karyotype, whereas untreated cells
expressed type A G6PD and the Ph1 chromosome. This reversal of G6PD
activity type and the disappearance of the Ph1 chromosome in colonies grown
from 4-HC-treated cells indicate that this cytotoxic agent spares a
residual normal stem cell population in bone marrow cells of early-phase
CML patients. This finding, in turn, suggests a therapeutic approach in CML
based on in vitro chemotherapy of autologous bone marrow grafts.
This article has been cited by other articles:
| |||||||||||
| Copyright © 1985 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||